FDA Immunotherapy Approvals Fell in 2025: 5 Things to Know

Why It Matters

The slowdown highlights tighter regulatory scrutiny that could reshape biotech development timelines, while the historic Chinese and anal‑cancer approvals broaden therapeutic options and open new market segments.

Key Takeaways

• FDA approved 13 immunotherapies in 2025, down from 22 in 2024.
• Checkpoint inhibitors accounted for 11 of 13 approvals, 77% since 2011.
• Penpulimab marks first Chinese immunotherapy cleared by FDA.
• Retifanlimab is first FDA‑approved immunotherapy for anal cancer.
• Approvals covered nine cancer types, showing broader disease focus.

Pulse Analysis

The dip in FDA immunotherapy approvals from 22 in 2024 to 13 in 2025 reflects a maturing regulatory landscape where agencies are demanding more robust efficacy and safety data. For biotech firms, this translates into longer trial timelines and higher development costs, prompting a strategic shift toward stronger early‑stage evidence and adaptive trial designs. Investors are watching these trends closely, as a tighter approval pipeline can compress revenue forecasts for companies heavily reliant on rapid market entry.

Despite the overall slowdown, immune‑checkpoint inhibitors continue to dominate the field, representing 77% of all approvals since 2011 and 11 of the 13 new agents in 2025. This concentration underscores the therapeutic potency of PD‑1/PD‑L1 pathways but also signals a need for diversification. The inclusion of a bispecific antibody and a cell‑and‑gene therapy among the 2025 slate hints at growing confidence in next‑generation modalities, which could eventually reshape standard‑of‑care protocols across multiple oncology indications.

The approval of Penpulimab, the first Chinese‑origin immunotherapy, and retifanlimab for anal cancer carries significant market implications. Penpulimab opens a new geographic pipeline, encouraging U.S. regulators to consider more foreign‑developed agents, while retifanlimab fills an unmet therapeutic gap, potentially driving adoption in a niche yet sizable patient population. Together, these milestones expand the competitive landscape, stimulate cross‑border collaborations, and promise broader patient access to innovative treatments in the years ahead.